Operating in over 30 countries
Operating in over 30 countries
The Regional Center Vienna (RCV), part of the German pharmaceutical company Boehringer Ingelheim, is responsible for over 30 countries in Central and Eastern Europe and in Asia. It is thus one of the company’s most important sites and is also a flagship enterprise in the Austrian capital. It employs around 1,500 people in medical research, production and administration.
As the center of Boehringer Ingelheim’s oncology research, Boehringer Ingelheim RCV GmbH & Co KG in Vienna is one of the most important sites within the global group of companies. We carry out research on new substances for cancer and other diseases and test them in clinical trials. The second focus is the development and production of biopharmaceuticals for ourselves and others.
As a regional center, we are responsible not only for the Austrian market but also for 33 countries in Central and Eastern Europe as far as Russia and Mongolia, and also Israel.
Our common goal is to achieve breakthroughs in the treatment of diseases and to advance medical research.
Vienna is special
The company’s expansion began in Vienna. The establishment of a subsidiary in 1948 was the first step towards the globalization of Boehringer Ingelheim. It was not only the first foreign subsidiary, however, but also the first site in the world where biopharmaceutical research was carried out. It was the birthplace in addition of biopharmaceutical production. We continue to invest heavily in Vienna. This benefits the company as a whole and also brings added value and attractive jobs to Vienna.
Boehringer Ingelheim - worldwide operations
Boehringer Ingelheim is one of the 20 leading pharmaceutical companies in the world. Its headquarters are in Ingelheim, Germany, and it has 145 affiliated companies worldwide. We provide secure jobs for over 50,000 people. In the last ten years alone we have added 10,000 employees to our workforce.
Boehringer Ingelheim is a family-owned company founded in 1885. Its main focuses are pharmaceutical research and the development, production, and marketing of new drugs with high therapeutic utility for human and veterinary medicine.
-
Vision
The Boehringer Ingelheim group of companies' objectives and beliefs can be summed up in a single phrase: Value through Innovation, the central concept of our corporate vision.
-
Who we are
We are proud to be honored with the international Prix Galien 2018 as an innovation and research leader in the field of Diabetes therapy.
-
BI Office Hours
Who we are
Boehringer Ingelheim invites innovative biomedical start-ups and entrepreneurs to join the next BI Office Hours at the Research Institute of Molecular Pathology (IMP). This is a great opportunity to benefit from BI’s science and business know-how.
-
Our Focus seeing clearly
Vision
Our Focus articulates who we are and what we strive for, how we work and what we want to achieve.
-
Medikamente
-
Annual Report
For over 130 years, Boehringer Ingelheim has continuously undergone change. Read more how agility drives us in our Annual Report 2017.
-
Speak up
Who we are
We commit to Compliance. Read here more about our Compliance and Speak up Culture.
-
-
PRESS RELEASE
A very successful 2016 financial year.
-
PRESS RELEASE
Boehringer Ingelheim can look back on a successful financial year.
-
DOWNLOAD PDF (1.41 MB)
Certificate Audit Work and Family -
Foto Zertifikatsverleihung
About Us
-
Logo Audit Beruf und Familie
-
Who we are
Video of the Austrian "Industriellenvereinigung" about Boehringer Ingelheim RCV GmbH & Co KG
-
History Milestone
-
History Milestone
-
History Milestone
-
Corporate
Get an overview of the major consolidated companies and our main business areas Human Pharmaceuticals and Animal Health
-
History
-
Management
As a family-owned company Boehringer Ingelheim is governed by the Board of Managing Directors composed of seven members. Read more about their respective responsibilities.